KalVista Pharmaceuticals (KALV) Depreciation & Amortization (CF) (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Depreciation & Amortization (CF) of $252000.0 in Q3 2025, up 14.55% quarter-over-quarter from $220000.0 in Q2 2025, and up 12.5% year-over-year from $224000.0 in Q3 2024.
KalVista Pharmaceuticals' Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $252000.0 for Q3 2025.
- In Q3 2025, Depreciation & Amortization (CF) rose 12.5% year-over-year to $252000.0; the TTM figure through Jul 2025 stood at $699000.0 (down 15.88% YoY), while the FY2025 annual figure was $900000.0, up 12.5% from the prior year.
- Depreciation & Amortization (CF) came in at $252000.0 for Q3 2025 at KalVista Pharmaceuticals, up from $220000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $252000.0 in Q3 2025 to a low of $127000.0 in Q4 2021.
- A 5-year average of $181277.8 and a median of $183000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) declined 4.51% in 2021 and surged 36.22% in 2022, its largest moves.
- KalVista Pharmaceuticals' Depreciation & Amortization (CF) stood at $127000.0 in 2021, then soared by 36.22% to $173000.0 in 2022, then advanced by 13.87% to $197000.0 in 2023, then climbed by 15.23% to $227000.0 in 2024, then grew by 11.01% to $252000.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $252000.0, $220000.0, and $227000.0 for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 252,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 252,000.00 |
| Jul 31, 2025 | 252,000.00 |
| Apr 30, 2025 | 220,000.00 |
| Apr 30, 2025 | 220,000.00 |
| Oct 31, 2024 | 227,000.00 |
| Oct 31, 2024 | 227,000.00 |
| Jul 31, 2024 | 224,000.00 |
| Jul 31, 2024 | 224,000.00 |
| Apr 30, 2024 | 203,000.00 |
| Apr 30, 2024 | 203,000.00 |
| Jan 31, 2024 | 207,000.00 |
| Jan 31, 2024 | 207,000.00 |
| Oct 31, 2023 | 197,000.00 |
| Oct 31, 2023 | 197,000.00 |
| Jul 31, 2023 | 193,000.00 |
| Jul 31, 2023 | 193,000.00 |
| Apr 30, 2023 | 170,000.00 |
| Apr 30, 2023 | 170,000.00 |
| Jan 31, 2023 | 199,000.00 |
| Jan 31, 2023 | 199,000.00 |
| Oct 31, 2022 | 173,000.00 |
| Oct 31, 2022 | 173,000.00 |
| Jul 31, 2022 | 158,000.00 |
| Jul 31, 2022 | 158,000.00 |
| Apr 30, 2022 | 156,000.00 |
| Apr 30, 2022 | 156,000.00 |
| Jan 31, 2022 | 149,000.00 |
| Jan 31, 2022 | 149,000.00 |
| Oct 31, 2021 | 127,000.00 |
| Oct 31, 2021 | 127,000.00 |
| Jul 31, 2021 | 132,000.00 |
| Jul 31, 2021 | 132,000.00 |
| Apr 30, 2021 | 140,000.00 |
| Apr 30, 2021 | 140,000.00 |
| Jan 31, 2021 | 136,000.00 |
| Jan 31, 2021 | 136,000.00 |
| Oct 31, 2020 | 133,000.00 |
| Oct 31, 2020 | 133,000.00 |
| Jul 31, 2020 | 128,000.00 |
| Jul 31, 2020 | 128,000.00 |
| Apr 30, 2020 | 130,000.00 |
| Apr 30, 2020 | 130,000.00 |
| Jan 31, 2020 | 134,000.00 |
| Jan 31, 2020 | 134,000.00 |
| Oct 31, 2019 | 127,000.00 |
| Oct 31, 2019 | 127,000.00 |
| Jul 31, 2019 | 121,000.00 |
| Jul 31, 2019 | 121,000.00 |
| Apr 30, 2019 | 122,000.00 |
| Apr 30, 2019 | 122,000.00 |
| Jan 31, 2019 | 103,000.00 |
| Jan 31, 2019 | 103,000.00 |
| Oct 31, 2018 | 103,000.00 |
| Oct 31, 2018 | 103,000.00 |
| Jul 31, 2018 | 50,000.00 |
| Jul 31, 2018 | 50,000.00 |
| Apr 30, 2018 | 51,000.00 |
| Apr 30, 2018 | 51,000.00 |
| Jan 31, 2018 | 50,000.00 |
| Jan 31, 2018 | 50,000.00 |
| Oct 31, 2017 | 47,000.00 |
| Oct 31, 2017 | 47,000.00 |
| Jul 31, 2017 | 32,000.00 |
| Jul 31, 2017 | 32,000.00 |
| Apr 30, 2017 | 11,000.00 |
| Apr 30, 2017 | 11,000.00 |
| Jan 31, 2017 | 10,000.00 |
| Jan 31, 2017 | 10,000.00 |
| Oct 31, 2016 | 11,000.00 |
| Oct 31, 2016 | 11,000.00 |
| Jul 31, 2016 | 8,000.00 |
| Jul 31, 2016 | 8,000.00 |
| Mar 31, 2016 | 34,000.00 |
| Mar 31, 2016 | 34,000.00 |
| Dec 31, 2015 | 35,000.00 |
| Dec 31, 2015 | 35,000.00 |
| Sep 30, 2015 | 33,000.00 |
| Sep 30, 2015 | 33,000.00 |
| Jun 30, 2015 | 34,000.00 |
| Jun 30, 2015 | 34,000.00 |
| Mar 31, 2015 | 31,000.00 |
| Mar 31, 2015 | 31,000.00 |
| Sep 30, 2014 | 17,000.00 |
| Sep 30, 2014 | 17,000.00 |
| Jun 30, 2014 | 10,000.00 |
| Jun 30, 2014 | 10,000.00 |
| Mar 31, 2014 | 10,000.00 |
| Mar 31, 2014 | 10,000.00 |